ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1886

GFB-887, a TRPC5 Inhibitor, Is Safe and Well Tolerated and Engages the TRPC5 Target, Leading to Reductions in Urinary Rac1 in Healthy Subjects

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Walsh, Liron, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Lynam, Chris, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Johnson, Leslie, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Ge, Tingting, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Pan-Zhou, Xin-Ru, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Czerwiec, Frank S., Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Dagon, Yossi, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Raghu, Hari, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Reilly, John F., Goldfinch Bio Inc, Cambridge, Massachusetts, United States
Background

Activation of the TRPC5-Rac1 pathway is a key driver of podocyte injury in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and diabetic nephropathy (DN). Inhibition of the TRPC5 ion channel may be a potential therapeutic target for these disorders. GFB-887 is a sub-type selective, small molecule TRPC5 ion channel inhibitor that has been shown in preclinical models to prevent podocyte damage mediated by Rac1 activation. This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) of GFB-887 in healthy subjects.

Methods

This is a phase 1, double-blinded, randomized, placebo-controlled, study in healthy subjects. The objectives were to characterize safety, tolerability, PK profile, and effects on urinary Rac1 after single oral doses of GFB-887. Subjects were randomized to either GFB-887 or placebo (8:2) in 5, 20, 40, 80,160, 320, and 900 mg SAD cohorts. Each subject received a single dose, had 24-hour urine collection pre and post-dose, and followed for 28 days post-dose.

Results

70 healthy subjects (median age 43 years, 86% male, 56% Caucasians, 42% African Americans) were dosed with GFB-887. The most common adverse event (AE) was headache. All AEs were mild and non-serious. There were no clinically significant changes in ECGs, vital signs or laboratory results. Blood pressure was modestly and asymptomatically reduced at the highest doses. Cmax and AUC of GFB-887 increased with higher doses in a less than dose proportionally manner through 900mg. Urinary Rac1 was significantly reduced from baseline with increasing doses of GFB-887.

Conclusion

Single doses of GFB-887 were well tolerated with a favorable PK profile in healthy subjects. GFB-887 exhibits dose-dependent reduction in urinary Rac1, a regulator of podocyte cytoskeletal structure and motility, indicating that GFB-887 engages and inhibits the TRPC5-Rac1 pathway. The safety and efficacy of GFB-887 is currently being evaluated in patients with FSGS, MCD, and DN (NCT04387448).

Funding

  • Commercial Support –